Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00743028 · ClinicalTrials.gov registry record · Phase 1
Assess the Oral Bioavailability of New ABT-263 Formulations
A Phase 1 study of Chronic Lymphocytic Leukemia and Lymphomas, sponsored by Abbott.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 5
- Study locations
NCT00743028 is a Phase 1 study of Chronic Lymphocytic Leukemia and Lymphomas that has completed, run by Abbott. The registered enrollment target is 36 participants, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (80% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT00743028, a Phase 1 study of Chronic Lymphocytic Leukemia and Lymphomas, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a randomized, open-label, multicenter crossover study to determine the oral bioavailability of new ABT-263 formulations relative to that of the current ABT-263 formulation being administered in ongoing Phase 1/2a studies. Approximately 36 evaluable subjects with lymphoid malignancies, including chronic lymphocytic leukemia, and solid tumors will be enrolled in this study.
Conditions Studied
Interventions
- DRUG ABT-263
Study Locations (5)
California
- Site Reference ID/Investigator# 10281 - Encinitas
- Site Reference ID/Investigator# 10282 - Santa Monica
Maryland
- Site Reference ID/Investigator# 16341 - Bethesda
New Hampshire
- Site Reference ID/Investigator# 9441 - Lebanon
New Jersey
- Site Reference ID/Investigator# 20041 - Hackensack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2008-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00743028
The ClinicalTrials.gov registry entry for NCT00743028 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (80% lower). The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which ABT-263 is the first listed.
NCT00743028 reports 5 study locations spanning 4 distinct geographic areas - top geographies include California, Maryland, New Hampshire.
Frequently Asked Questions
What is clinical trial NCT00743028 about?
NCT00743028 is a clinical study titled "Assess the Oral Bioavailability of New ABT-263 Formulations". This is a randomized, open-label, multicenter crossover study to determine the oral bioavailability of new ABT-263 formulations relative to that of the current ABT-263 formulation being administered in ongoing Phase 1/2a studies. Approximately 36 evaluable subjects with lymphoid malignancies, includ...
What is the current status of trial NCT00743028?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2008-08.
What conditions does trial NCT00743028 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, Lymphomas, Leukemias.
What interventions are being tested in trial NCT00743028?
The interventions under investigation include: ABT-263 (DRUG).
Who is sponsoring clinical trial NCT00743028?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00743028 being conducted?
This trial has 5 study locations across California, Maryland, New Hampshire, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
RECRUITING · Phase 1
-
Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
RECRUITING · Phase 1
-
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
RECRUITING · Phase 1
-
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.